Mi az ára National Graphite Corp. (NGRC)

National Graphite Corp. (NGRC) ára $0.021

Mi a National Graphite Corp. (NGRC piaci tőkésítése)

National Graphite Corp. piaci tőkésítése (NGRC) $3.24M

National Graphite Corp. (NGRC) Egy Részvényre Jutó Nyereség

National Graphite Corp. (NGRC), operating through its subsidiary Biotech Development Corp., functions as a biopharmaceutical enterprise specializing in risk and cost-sharing models. The company establishes partnerships with clinical-stage firms dedicated to developing novel biological entities or innovative therapeutic platforms. These collaborations aim to address a wide spectrum of health conditions, encompassing common illnesses, rare disorders, and those with significant unmet medical requirements. Among its key pipeline developments is ELAFIN, a drug candidate identified as a human-identical protein. ELAFIN is being developed specifically for the management of postoperative inflammatory complications. The advancement of ELAFIN is further supported by a collaboration agreement with Proteo Inc. Founded in 2006, National Graphite Corp. was formerly known as Lucky Boy Silver Corporation until it officially adopted its current name in May 2012. The company maintains its operational headquarters in Duesseldorf, Germany.

Év	EPS	Változtassa meg
Nincs elég adat a megadott dátumokhoz.

Év

EPS

Változtassa meg

Nincs elég adat a megadott dátumokhoz.

Vállalat	EPS	EPS különbség	Ország
Clone Algo Technologies Inc. CATI.US	-	-	US
Worldwide Webb Acquisition Corp. WWAC.US	-	-	US
Gushen, Inc. GSHN.US	-	-	CN
Apollo Strategic Growth Capital APSG.US	-	-	US
Digital World Acquisition Corp. DWAC.US	-	-	US

Vállalat

EPS

EPS különbség

Ország